The aim of this article was to evaluate the prognostic value of metabolic tumor volume (MTV) and total lesion glycolysis (TLG) on preoperative F-FDG PET/CT for predicting intrahepatic recurrence-free survival (IHRFS), extrahepatic metastasis-free survival (EHMFS), and overall survival (OS) in patients with very early/early hepatocellular carcinoma (HCC).
The comparison of the imaging results of the two methods showed that <sup>99m</sup>Tc-3PRGD<sub>2</sub> integrin receptor imaging was more sensitive than <sup>18</sup>F-FDG metabolic imaging for the detection of early stage HCC, meanwhile the tumour uptake of <sup>99m</sup>Tc-3PRGD<sub>2</sub> was consistently higher than that of <sup>18</sup>F-FDG.
The in vitro cellular uptake, in vivo micro-PET/CT imaging and biodistribution studies of 68Ga-NGR and 18F-FDG were quantitatively compared in SMMC-7721-based well‑differentiated HCC xenografts.
Pretreatment tumour metabolic activity assessed by <sup>18</sup>F-FDG PET is an independent prognostic factor for survival in patients with BCLC-C stage HCC receiving sorafenib monotherapy, although it may not predict tumour response to the treatment.
Signature of survival: a <sup>18</sup>F-FDG PET based whole-liver radiomic analysis predicts survival after <sup>90</sup>Y-TARE for hepatocellular carcinoma.
Decrease in TLG measured by F-FDG PET-CT is correlated with a trend towards a longer median survival in patients affected by HCC and PVTT who have undergone Y-RE.
The sensitivity, specificity and accuracy values of contrast-enhanced <sup>18</sup>F-FDG PET/CT examination in the detection of HCC recurrence were 92.8%, 94.1% and 93%, respectively.
Similarly, pooled specificity was comparable with CT (93%) or without 95% (P = .481).F-FDG PET, with or without CT, shows relatively low sensitivity but high specificity for diagnosing extrahepatic metastases or local residual/recurrent HCC.
This study aimed to examine tumoral and background standardized uptake value (SUV) alterations in dual-phase F-FDG PET/computed tomography (CT) imaging.Fifty-two HCC cases underwent dual-time-point F-FDG PET/CT examination where early and delayed images were obtained.
A 53-year-old man with tentative diagnosis of likely hepatocellular carcinoma underwent FDG PET/CT, which showed intense activity in both right lobe and caudate lobe of the liver.
18F-FDG PET/CT predicts microvascular invasion and early recurrence after liver resection for hepatocellular carcinoma: A prospective observational study.
Despite the observed reasonable diagnostic performance of FDG-PET SUV<sub>max</sub> for HCC detection and several significant correlations between FDG-PET SUV and DCE-MRI parameters, FDG-PET did not provide clear additional value for HCC characterization compared to mpMRI in this pilot study.
In addition to HCC diagnosis, since the degree of 18F-FDG uptake converted to standardized uptake value (SUV) correlates well with tumor aggressiveness, 18F-FDG PET/CT scans can predict patient outcomes such as treatment response and survival with an inverse relationship between SUV and survival.
The images showed abnormal FDG uptake in the left lobe and hilum of the liver, which was confirmed as hepatocellular carcinoma and hepatic portal bile duct tumor thrombus, respectively, by the pathology.